Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962280 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
A Phase 3 study of Obesity and Type 1 Diabetes, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 465
- Enrollment target
- 20
- Study locations
NCT06962280: Active Phase 3 study of Obesity and Type 1 Diabetes, sponsored by Eli Lilly and Company.
NCT06962280 is a Phase 3 study of Obesity and Type 1 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 465 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06962280, a Phase 3 study of Obesity and Type 1 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 465 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Texas
- Velocity Clinical Research, Dallas - Dallas
- Juno Research - Houston
- Southern Endocrinology Associates - Mesquite
- Texas Diabetes & Endocrinology, P.A. - Round Rock
- San Antonio Clinical Trials - San Antonio
- Texas Valley Clinical Research - Weslaco
California
- Kaiser Permanente Bonita Medical Offices - Bonita
- AMCR Institute - Escondido
- Mary & Dick Allen Diabetes Center - Newport Beach
- University Clinical Investigators, Inc. - Tustin
Missouri
- Clinical Research Professionals - Chesterfield
- Clinvest Headlands Llc - Springfield
Other
- Buenos Aires Macula S.A - Buenos Aires
- Stat Research S.A. - Buenos Aires
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- Metabolic Research Institute, Inc. - West Palm Beach
Iowa
- Iowa Diabetes and Endocrinology Research Center - West Des Moines
Minnesota
- HealthPartners Institute dba International Diabetes Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
What the registry record for NCT06962280 still lists
NCT06962280 is an interventional study that assigns participants to a tested intervention. The registered 465 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (43% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06962280 names 20 study sites across 10 states, led by Texas, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06962280 about?
NCT06962280 is a clinical study titled "A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight". The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
What is the current status of trial NCT06962280?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2025-05-12. Estimated completion is 2027-07.
What conditions does trial NCT06962280 study?
This clinical trial studies the following conditions: Obesity, Type 1 Diabetes, Overweight.
What interventions are being tested in trial NCT06962280?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06962280?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06962280 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06962280's enrollment target sits among peer trials
465 148th of 1053 higher than 906 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717698 · 465 participants · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- NCT07420283 · 465 participants · Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI